EU approves first of a new class of diabetes drugs

11/15/2012 | Reuters · Miami Herald (free registration), The

The European Commission approved Bristol-Myers Squibb and AstraZeneca's Forxiga, or dapagliflozin, to treat adults with type 2 diabetes. The decision makes Forxiga the first approved treatment from a new class of drugs called SGLT2 inhibitors. Forxiga, which works independently of insulin to regulate blood sugar, can be taken in combination with other type 2 diabetes drugs, or as a standalone therapy for patients who can't tolerate metformin. In January, the FDA did not approve the drug over concerns about liver and cancer risks.

View Full Article in:

Reuters · Miami Herald (free registration), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI